Skip to main content

Table 2 Patient Response Evaluation

From: Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

  All (N = 54) Group 1 (N = 13) Group 2 (N = 31) Group 3 (N = 10)
TTP (days)
 Naïve B-cell 44 71 35
 Naïve T-cell 31 31 32.5
 Relapsed B-cell 24 19 23 85
 Relapsed T-cell 43 43 73 24
Objective Response (n)
 Naïve B-cell 8 4 4
 Naïve T-cell 5 1 4
 Relapsed B-cell 4 1 1 2
 Relapsed T-cell 4 1 2 1